Pulse Biosciences Files 8-K

TL;DR

Pulse Biosciences filed an 8-K on July 3rd, nothing major but good to keep an eye on.

AI Summary

Pulse Biosciences, Inc. filed an 8-K on July 3, 2024, to report other events and financial statements. The company, formerly known as Electroblate, Inc., is incorporated in Delaware and headquartered in Hayward, California.

Why It Matters

This filing indicates routine corporate updates and financial reporting for Pulse Biosciences, Inc., providing transparency to investors.

Risk Assessment

Risk Level: low — This is a standard 8-K filing for corporate events and financial statements, not indicating any immediate significant risks.

Key Numbers

• 001-37744 — SEC File Number (Identifies the company's filing with the SEC.)
• 46-5696597 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Pulse Biosciences, Inc. (company) — Registrant
• July 3, 2024 (date) — Date of Report
• Electroblate, Inc. (company) — Former Company Name
• Delaware (jurisdiction) — State of Incorporation
• Hayward, California (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock , par value $0.001 per share PLSE The Nasdaq Stock Mar
• $10.00 — purchase 6,000,000 units, at a price of $10.00 per unit, with each unit consisting of
• $11.00 — ny common stock at an exercise price of $11.00 per whole share. The Company has receiv
• $60 million — ate gross proceeds from the offering of $60 million. After giving effect to the issuance of

Filing Documents

• plse20240702_8k.htm (8-K) — 28KB
• ex_695236.htm (EX-99.1) — 14KB
• 0001437749-24-022162.txt ( ) — 177KB
• plse-20240703.xsd (EX-101.SCH) — 3KB
• plse-20240703_def.xml (EX-101.DEF) — 11KB
• plse-20240703_lab.xml (EX-101.LAB) — 15KB
• plse-20240703_pre.xml (EX-101.PRE) — 11KB
• plse20240702_8k_htm.xml (XML) — 3KB

01

ITEM 8.01 Other Events. On July 3, 2024, Pulse Biosciences, Inc. (the "Company") issued a press release announcing the closing and final results of its previously announced rights offering. In the offering, eligible stockholders subscribed to purchase 6,000,000 units, at a price of $10.00 per unit, with each unit consisting of one share of Company common stock and two warrants each to purchase one half share of Company common stock at an exercise price of $11.00 per whole share. The Company has received aggregate gross proceeds from the offering of $60 million. After giving effect to the issuance of 5,999,999 shares of common stock in the rights offering (but excluding up to approximately six million shares of common stock underlying the warrants issued in the rights offering), the Company has 61,228,332 shares of common stock issued and outstanding. A copy of the press release related to the matters set forth herein is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release issued by Pulse Biosciences, Inc. dated July 3, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PULSE BIOSCIENCES, INC. Date: July 3, 2024 By: /s/ Burke T. Barrett Burke T. Barrett President and Chief Executive Officer (Principal Executive and Principal Financial Officer)

View Full Filing

View this 8-K filing on SEC EDGAR